ArticleEuropean radiology2022
How to improve O-RADS MRI score for rating adnexal masses with cystic component?
Article in European radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Performance of MRI protocols for diagnosis of benign and malignant ovarian tumors: a systematic review and meta-analysis.Abdominal radiology (New York) · 2026Pooled it
- Diagnostic accuracy of a modified non-contrast O-RADS MRI scoring system: a retrospective study.Insights into imaging · 2026Article
- Magnetic resonance biomarkers in detection and characterisation of ovarian cancer: is magnetic resonance spectroscopy ready for clinical use?Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Review
- Diagnostic reliability of O-RADS score based on non-dynamic contrast-enhanced MRI and apparent diffusion coefficient in characterization of adnexal masses.BMC medical imaging · 2026Article
- Follow-up MRI recommendations for adnexal lesions on pelvic ultrasound: frequency, associations and outcomes.Abdominal radiology (New York) · 2026Article
- How to integrate O-RADS MRI scores with clinical and imaging criteria to predict histopathological subtypes.European radiology · 2026Article
- The added value of apparent diffusion coefficient assessments in O-RADS MRI evaluation for characterizing ovarian masses with solid components.Abdominal radiology (New York) · 2026Article
- Article
- Role of Imaging Techniques in Ovarian Cancer Diagnosis: Current Approaches and Future Directions.Cancers · 2026Review
- Radiomics-based MRI model for differentiating ovarian cystadenoma and cystadenocarcinoma.Frontiers in oncology · 2026Article
- Diagnostic value of multiparametric MRI combined with an interpretable machine learning model in the differentiation of benign and malignant ovarian-adnexal lesions classified as O-RADS 4.BMC medical imaging · 2025Article
- Review
- Differentiating struma ovarii from FIGO stage I malignant ovarian tumors in O-RADS MRI 5 lesions: a targeted cohort study.Abdominal radiology (New York) · 2025Article
- Diagnostic performance of a modified O-RADS classification system for adnexal lesions incorporating clinical features.Abdominal radiology (New York) · 2025Article
- Efficacy of a combination of O-RADS, CEUS, and CA125, in identification of ovary-adnexal malignant lesions.American journal of cancer research · 2025Article
- O-RADS MRI scoring system: key points for correct application in inexperienced hands.Insights into imaging · 2024Article
- O-RADS MRI to classify adnexal tumors: from clinical problem to daily use.Insights into imaging · 2024Article
- O-RADS MRI: where are we and where we are going?European radiology · 2023Article
- Improving risk stratification of indeterminate adnexal masses on MRI: What imaging features help predict malignancy in O-RADS MRI 4 lesions?European journal of radiology · 2023Article
- Ovarian-Adnexal Reporting and Data System for Magnetic Resonance Imaging (O-RADS MRI): Genesis and Future Directions.Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes · 2023Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo test the performance of the Ovarian-Adnexal Reporting Data System (O-RADS) MRI in characterizing adnexal masses with cystic components and to test new specific MRI features related to cystic components to improve the ability of the O-RADS MRI score to stratify lesions according to their risk of malignancy.
methodsThe EURopean ADnexal study (EURAD) database was retrospectively queried to identify adnexal masses with a cystic component. One junior and 13 radiologists independently reviewed cases blinded to the pathological diagnosis. For each lesion, the size of the whole lesion, morphological appearance, number of loculi, presence of a thickened wall, thickened septae, signal intensity of the cystic components on T1-weighted/T2-weighted/diffusion weighted, mean value of the apparent diffusion coefficient, and O-RADS MRI score were reported. Univariate and multivariate logistic regression analysis was performed to determine significant features to predict malignancy.
resultsThe final cohort consisted of 585 patients with 779 pelvic masses who underwent pelvic MRI to characterize an adnexal mass(es). Histology served as the standard of reference. The diagnostic performance of the O-RADS MRI score was 0.944,
conclusionCystic component analysis may improve the diagnosis performance of the O-RADS MRI score in adnexal cystic masses. KEY POINTS: • O-RADS MRI score combined with specific cystic features (area under the receiving operating curve, AUROC = 0.958) improves the diagnostic performance of the O-RADS MRI score (AUROC = 0.944) for predicting malignancy in this cohort. • Cystic features that improve the prediction of malignancy are ADC mean > 1.69 (OR = 7); number of loculi ≥ 3 (OR = 5.16); lesion size > 75 mm (OR = 4.40); the presence of a thick wall (OR = 3.59); a high T2-weighted signal intensity score 4 or 5 (OR = 3.30); a low T1-weighted signal intensity score 1, 2, or 3 (OR = 3.45); and a low diffusion-weighted signal intensity (OR = 2.12). • An adnexal lesion with a cystic component rated O-RADS MRI score 4 and an ADC value of the cystic component < 1.69 associated with a low diffusion-weighted signal, has virtually a 0% risk of malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.